Latanoprost: Nursing Drug Guide, Iris Pigmentation & NCLEX Review

The reference brand is XALATAN (latanoprost ophthalmic solution 0.005% [50 mcg/mL]). Multiple generic latanoprost 0.005% bottles are available—verify concentration and expiration dating, especially after opening (six weeks at room temperature per XALATAN labeling).

Combination regimens often pair latanoprost with beta-blockers such as timolol, carbonic anhydrase inhibitors such as dorzolamide, or alpha-agonists such as brimonidine—separate each topical ophthalmic drug by at least five minutes per prescribing information. Do not combine two prostaglandin analogs (e.g., latanoprost plus bimatoprost) unless the prescriber explicitly orders otherwise.

XALATAN is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Nurses support outpatient adherence, teach long-term pigmentation counseling, and coordinate ophthalmology follow-up for pressure targets.

↔On a small screen, swipe or scroll sideways to see the full table.

Latanoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing aqueous humor outflow; studies suggest the main mechanism is increased uveoscleral outflow. Elevated IOP is a major risk factor for glaucomatous optic nerve damage; nursing focus is on consistent evening dosing, technique that prevents bottle contamination, and early recognition of hyperemia or inflammatory symptoms that may require prescriber review.

The recommended dosage is one drop (approximately 1.5 mcg latanoprost) in the affected eye(s) once daily in the evening. If one dose is missed, treatment continues with the next dose as normal. The dosage of XALATAN must not exceed once daily; combined use of two or more prostaglandin analogs is not recommended per labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Confirm allergy history and active intraocular inflammation (e.g., uveitis)—prostaglandin analogs may exacerbate inflammation
• Review history of herpetic keratitis and aphakic/pseudophakic status with macular edema risk; perform medication reconciliation for other topical eye drops and spacing requirements
• Document iris color baseline and counsel that increased brown pigmentation of the iris may be permanent; verify order frequency is once daily in the evening

Contraindications

• Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in the product

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Topical ophthalmic solution. Follow medication administration rights and institutional eye care protocols when teaching or supervising instillation.

• Wash hands; remove contact lenses before the drop; tilt head back, pull down lower lid, instill one drop without allowing the dispenser tip to contact the eye, eyelid, lashes, fingers, or any surface
• Close the eye gently for 30–60 seconds; optional punctal occlusion for one minute may reduce systemic absorption per local protocol
• Administer in the evening once daily; if using multiple topical agents, wait at least five minutes between different drops
• Replace cap immediately; store unopened bottles refrigerated at 2°C to 8°C (36°F to 46°F); after opening, store at room temperature up to 25°C (77°F) for six weeks per XALATAN labeling

• Gradual reduction in intraocular pressure on ophthalmology tonometry—clinical trials with XALATAN 0.005% once daily in the evening report approximately 6–8 mmHg reductions from mean baseline IOP of 24–25 mmHg over six months
• Stable vision without new progressive vision changes beyond expected mild, often transient conjunctival hyperemia
• Patient demonstrates correct evening technique, contact-lens timing, and understanding that iris pigmentation may increase over months of therapy

Escalate urgently for findings suggesting infection, severe inflammation, or acute vision threat. Hold the drop and notify the prescriber or pharmacist when in doubt.

• Severe or worsening eye pain, photophobia, purulent discharge, or corneal opacity suggesting keratitis
• Acute blurred vision or field loss distinct from mild, expected hyperemia
• Active herpes simplex keratitis or inflammation flare in a patient with prior uveitis or herpetic keratitis history
• Hypersensitivity—eye allergy symptoms, rash, bronchospasm, or periorbital anaphylaxis after dosing
• Suspected bottle contamination or patient using drops more than once daily without order clarification

↔On a small screen, swipe or scroll sideways to see the full table.

If overdosage with XALATAN occurs, treatment should be symptomatic per labeling. Topical extra drops do not improve IOP control and may increase ocular irritation; do not exceed once-daily dosing. IV overdosage data in labeling describe abdominal pain, dizziness, nausea, and sweating at high systemic doses—topical overdose is unlikely to produce those effects. No specific antidote is specified in the reviewed prescribing information.

• Latanoprost vs bimatoprost vs travoprost—all prostaglandin analogs with similar bottles; verify generic name on the label
• XALATAN 0.005% vs other glaucoma bottles—turquoise cap on brand XALATAN; do not substitute another patient’s bottle
• Evening QHS vs BID timolol—patients may confuse schedules when using multiple glaucoma bottles
• Right eye vs left eye—document affected eye(s) on the MAR; pigmentation changes may be asymmetric
• Shared household bottles—each patient needs a dedicated dispenser to prevent cross-contamination

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Intraocular pressure per ophthalmology schedule; symptom review for hyperemia, pain, and vision changes at each visit or telehealth check-in
• Iris, eyelid, and lash pigmentation as well as eyelash growth asymmetry between eyes
• Signs of intraocular inflammation or corneal infection, especially if the patient reports technique lapses

Document

• Pre-treatment pigmentation counseling, affected eye(s), evening dose time, and contact-lens removal/reinsertion teaching
• Demonstration of drop instillation without tip contamination; patient/caregiver teach-back when applicable
• Adverse effects reported and prescriber/pharmacist notifications

• Your iris color may permanently darken, usually as increased brown pigmentation spreading from the pupil—this may not be noticeable for months
• Use exactly one drop in the affected eye(s) once daily in the evening; do not use extra drops or morning doses
• Do not let the bottle tip touch your eye, fingers, or any surface; replace the cap immediately after use
• Remove soft contact lenses before the drop and wait 15 minutes before putting them back in
• Expect eyelash changes (length, thickness, number)—usually reversible after stopping treatment
• Contact your eye care team promptly for eye pain, sudden vision change, discharge, or signs of allergy

Do not instill and contact the prescriber or pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for latanoprost using a tabbed outpatient glaucoma case (MAR, labs, history, nursing notes), then priority action, cue recognition, IOP trend interpretation, matrix urgency sorting, prostaglandin-dosing safety, and contact-lens timing cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.